NSCLC Harboring NRG1 Fusion clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.
at UC Irvine